Joanne Estell joins Shield Therapeutics as CFO
Shield Therapeutics has announced that it has recruited Joanne Estell as its new CFO and board member; she will step into the role on 1 May. Most recently serving technology manufacturer Stadium Group as its CFO and Company Secretary, Estell brings over 20 years’ experience to the role, with particular expertise in strategy, senior finance and mergers & acquisitions.
Throughout her career, she has held positions including Head of Mergers & Acquisitions at Survitec Group, alongside roles at Whitbread and Smiths Group. She also boasts previous directorships at more than 20 companies.
“Joanne has an exceptional track record and I am delighted to welcome her to Shield Therapeutics as our CFO,” commented Shield CEO and Founder Carl Sterritt. “She brings a wealth of finance experience from listed international businesses and has strong ambitions that are aligned with ours. Having evaluated, developed and delivered corporate growth strategies, the Board and I are particularly looking forward to working closely with Joanne as she plays a pivotal role in Shield’s ongoing journey towards becoming a fully‐fledged, international and commercially‐focused specialty pharmaceutical business.”
Estell herself added: “I am delighted to be joining Shield Therapeutics at this exciting time in its rapid development. With Feraccru now firmly on the market, Shield is delivering growing revenues and expanding its reach within existing markets as well as planning for further international expansion. By working closely with Carl and Shield’s highly experienced and driven wider team, my focus will be on effectively supporting our ambitious growth plans so we can deliver increasing value to our shareholders.”